EMMA Stock Overview
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.31 |
52 Week High | US$0.60 |
52 Week Low | US$0.071 |
Beta | 1.92 |
1 Month Change | -1.59% |
3 Month Change | -18.42% |
1 Year Change | -16.22% |
3 Year Change | -80.75% |
5 Year Change | n/a |
Change since IPO | -96.84% |
Recent News & Updates
Recent updates
Shareholder Returns
EMMA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 3.3% | -2.7% | 0.06% |
1Y | -16.2% | -4.9% | -0.7% |
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: EMMA underperformed the US Market which returned -0.7% over the past year.
Price Volatility
EMMA volatility | |
---|---|
EMMA Average Weekly Movement | 14.3% |
Pharmaceuticals Industry Average Movement | 10.6% |
Market Average Movement | 6.5% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EMMA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: EMMA's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 55 | Yutaka Niihara | https://www.emmausmedical.com |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
Emmaus Life Sciences, Inc. Fundamentals Summary
EMMA fundamental statistics | |
---|---|
Market Cap | US$16.63m |
Earnings (TTM) | -US$12.61m |
Revenue (TTM) | US$21.91m |
0.8x
P/S Ratio-1.3x
P/E RatioIs EMMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EMMA income statement (TTM) | |
---|---|
Revenue | US$21.91m |
Cost of Revenue | US$2.01m |
Gross Profit | US$19.90m |
Other Expenses | US$32.51m |
Earnings | -US$12.61m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.24 |
Gross Margin | 90.83% |
Net Profit Margin | -57.56% |
Debt/Equity Ratio | -83.2% |
How did EMMA perform over the long term?
See historical performance and comparison